Optimizing Prostate Cancer Management: Leveraging PSMA Imaging to Enhance Treatment Strategies : Episode 3
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
Panelists discuss how medical professionals select PSMA PET tracers based on factors such as diagnostic accuracy, tracer availability, patient-specific considerations, and logistical aspects such as half-life and production facilities. Fluorine-18 (^18F)–labeled tracers, such as ^18F-PSMA-1007, offer logistical advantages due to their longer half-life and higher image resolution, facilitating broader clinical application.
EP: 1.The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
EP: 2.PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
Now Viewing
EP: 3.Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
EP: 4.Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Video content above is prompted by the following:
- What factors do you consider when selecting a PSMA PET tracer for a particular patient or clinical scenario?
- When might you opt for F18 vs Ga58, and how do available data inform your decision?
- Meta-analysis F18 vs G68 (Huang et al. Prostate Cancer. 2023)
- Do you still see a role for Axumin? If so, in what scenarios?
Recent Videos
Related Content
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025Podcast
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
